AAM
BBIO icon

Alphadyne Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Alphadyne Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,000
Closed -$520K – 895
2026
Q1 		$520K Buy
+7,000
New +$507K 0.01% 683

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Alphadyne Asset Management's BBIO Position: Q2 2026 in Review

Alphadyne Asset Management sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 1,014 shares — an estimated $75.3K sold.

Alphadyne Asset Management first reported a position in BBIO in Q1 2026 and held it in 1 quarter. The position peaked at $75.3K in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Alphadyne Asset Management reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Alphadyne Asset Management sold 1,014 BridgeBio Pharma shares in Q2 2026, an estimated $75.3K.
  • Alphadyne Asset Management first reported a position in BridgeBio Pharma in Q1 2026 and held it in 1 quarter.
  • Alphadyne Asset Management's BridgeBio Pharma position peaked at $75.3K in Q1 2026.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Alphadyne Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.